EGFR Inhibition in Glioma Cells Modulates Rho Signaling to Inhibit Cell Motility and Invasion and Cooperates with Temozolomide to Reduce Cell Growth

Enforced EGFR activation upon gene amplification and/or mutation is a common hallmark of malignant glioma. Small molecule EGFR tyrosine kinase inhibitors, such as erlotinib (Tarceva), have shown some activity in a subset of glioma patients in recent trials, although the reported data on the cellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramis, Guillem, Thomàs-Moyà, Elena, Fernández de Mattos, Silvia, Rodríguez, José, Villalonga, Priam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368887/
https://www.ncbi.nlm.nih.gov/pubmed/22701710
http://dx.doi.org/10.1371/journal.pone.0038770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368887/
https://www.ncbi.nlm.nih.gov/pubmed/22701710
http://dx.doi.org/10.1371/journal.pone.0038770

Ejemplares similares